Obstructive Lung Disease

Smoking Marijuana May Increase Cough, Sputum Production, and Wheezing

Smoking Marijuana May Increase Cough, Sputum Production, and Wheezing

By

Results of a pooled analysis of cross-sectional studies demonstrated an increase in cough, sputum production, wheezing, and dyspnea from marijuana use.

Azithromycin Reduced Pulmonary Exacerbation Risk in Cystic Fibrosis

Azithromycin Reduced Pulmonary Exacerbation Risk in Cystic Fibrosis

By

Compared with placebo, the risk for a pulmonary exacerbation was reduced by 44% in participants with cystic fibrosis who received azithromycin.

<i>Aspergillus</i> Common in Bronchiectasis Pulmonary Mycobiome, Associated With Exacerbations

Aspergillus Common in Bronchiectasis Pulmonary Mycobiome, Associated With Exacerbations

By

Bronchiectasis-associated genera included Aspergillus, Cryptococcus, Clavispora, Botrytis, and Alternaria.

Ivacaftor Decreases Mortality, Hospitalization in Cystic Fibrosis

Ivacaftor Decreases Mortality, Hospitalization in Cystic Fibrosis

By

Ivacaftor decreased the risk for death, transplantation, hospitalization, and pulmonary exacerbation in patients with cystic fibrosis.

Lung Function in Cystic Fibrosis Affected by Sputum Viscoelasticity and Poor Clearance

Lung Function in Cystic Fibrosis Affected by Sputum Viscoelasticity and Poor Clearance

By

Sputum viscoelastic properties were associated with lung function and disease status in patients with cystic fibrosis.

Novel Cystic Fibrosis Treatment Granted Fast Track Status

Novel Cystic Fibrosis Treatment Granted Fast Track Status

By

Proteostasis Therapeutics is developing the combination treatment which includes a novel transmembrane conductance regulator (CFTR) amplifier (PTI-428), a third generation corrector (PTI-801) and a potentiator (PTI-808).

Cystic Fibrosis-Related Pathogen Risk With Chronic Azithromycin Use

Cystic Fibrosis-Related Pathogen Risk With Chronic Azithromycin Use

By

Patients with cystic fibrosis who took azithromycin had a significantly lower risk for detection of new nontuberculous mycobacteria, methicillin-resistant Staphylococcus aureus, and Burkholderia cepacia complex.

Cystic Fibrosis Foundation Recommends CFTR Modulator Therapy in Select Patients

Cystic Fibrosis Foundation Recommends CFTR Modulator Therapy in Select Patients

By

CFTR modulator therapy recommended in certain patients with cystic fibrosis.

CFTR Modulator Therapy With Tezacaftor-Ivacaftor in Cystic Fibrosis

CFTR Modulator Therapy With Tezacaftor-Ivacaftor in Cystic Fibrosis

By

Effective cystic fibrosis transmembrane conductance regulator modulator therapy may be of benefit in subsets of patients with cystic fibrosis.

Cystic Fibrosis: More Access to Advanced Care Planning, Palliative Care Needed

Cystic Fibrosis: More Access to Advanced Care Planning, Palliative Care Needed

By

Palliative care access may be limited for patients with cystic fibrosis.

ADHD in Cystic Fibrosis: Prevalence, Screening, and Treatment

ADHD in Cystic Fibrosis: Prevalence, Screening, and Treatment

By

The Adult ADHD Self-Report Scale-v1.1 Symptom Checklist may be able to detect previously undiagnosed ADHD in patients with cystic fibrosis.

Sleep Disordered Breathing and Risk of Cognitive Impairment Linked

Sleep Disordered Breathing and Risk of Cognitive Impairment Linked

Data from 200 participants were analyzed to determinet he link between sleep disordered breathing, cognitive function, and cognitive impairment.

Respiratory Microbiome Changes May Affect Airway Inflammation in Cystic Fibrosis

Respiratory Microbiome Changes May Affect Airway Inflammation in Cystic Fibrosis

By

Lower microbial diversity in the respiratory tract in patients with cystic fibrosis was linked with prophylactic antibiotics and less airway inflammation.

Predicting Severity in Cystic Fibrosis With Sweat Chloride

Predicting Severity in Cystic Fibrosis With Sweat Chloride

By

Sweat chloride can predict severity in patients with CF, especially for long-term lung damage.

Lumacaftor/Ivacaftor Safe, Effective for Pediatric Cystic Fibrosis

Lumacaftor/Ivacaftor Safe, Effective for Pediatric Cystic Fibrosis

By

Combination lumacaftor/ivacaftor therapy was found to be safe and effective in patients with cystic fibrosis aged 6 to 11 years.

Atorvastatin Improves Quality of Life in Patients With Bronchiectasis

Atorvastatin Improves Quality of Life in Patients With Bronchiectasis

By

Statin therapy reduces inflammation and improves quality of life in patients with severe bronchiectasis infected with P aeruginosa.

Efficacy of Home Noninvasive Ventilation With Oxygen Therapy in COPD, Hypercapnia

Efficacy of Home Noninvasive Ventilation With Oxygen Therapy in COPD, Hypercapnia

By

Patients with persistent hypercapnia following acute exacerbation of COPD, home noninvasive ventilation with home oxygen therapy prolonged readmission time.

Increase in Asthma and Allergy Symptoms Impacted by Climate Change

Increase in Asthma and Allergy Symptoms Impacted by Climate Change

The rise in asthma and allergy symptoms may be due to climate change which heightens the damage of airway cells by outdoor fungus.

NIH: National Action Plan Unifies Approach to Ending US COPD Crisis

NIH: National Action Plan Unifies Approach to Ending US COPD Crisis

By

The release of a new autonomous approach for terminating the COPD crisis has been lead by the National Heart, Lung and Blood Institute (NHLBI).

Reducing Exacerbations in Moderate-to-Severe COPD With Beta-Blocker Therapy

Reducing Exacerbations in Moderate-to-Severe COPD With Beta-Blocker Therapy

By

Researchers examined the relationship between COPD and right and left ventricular morphometry to determine which patients may better respond to beta-blocker therapies.

FDA Expands Approved Use of Ivacaftor for Cystic Fibrosis

FDA Expands Approved Use of Ivacaftor for Cystic Fibrosis

By

The FDA has expanded the approved indication of ivacaftor for cystic fibrosis, increasing the number of rare gene mutations the drug may be used to treat.

Sign Up for Free e-newsletters